Analyst Price Targets — HCAT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 20, 2026 8:16 pm | — | Canaccord Genuity | $1.80 | $1.63 | TheFly | Canaccord downgrades Health Catalyst to Hold on transformation risk |
| July 21, 2026 10:52 am | — | Canaccord Genuity | $3.00 | $2.16 | TheFly | Health Catalyst price target raised to $3 from $2 at Canaccord |
| June 26, 2026 10:01 am | Stan Berenshteyn | Wells Fargo | $1.75 | $1.77 | TheFly | Health Catalyst price target raised to $1.75 from $1 at Wells Fargo |
| May 12, 2026 11:33 am | — | Stephens | $1.75 | $1.38 | TheFly | Health Catalyst price target lowered to $1.75 from $2 at Stephens |
| March 13, 2026 11:24 am | Sarah James | Raymond James | $3.00 | $1.79 | StreetInsider | Health Catalyst Inc. (HCAT) PT Lowered to $3 at Cantor Fitzgerald; No Turnaround Yet |
| March 13, 2026 11:14 am | Richard Close | Canaccord Genuity | $2.00 | $1.79 | StreetInsider | Health Catalyst Inc. (HCAT) PT Lowered to $2 at Canaccord |
| October 8, 2025 12:11 pm | — | Evercore ISI | $3.00 | $2.90 | TheFly | Health Catalyst price target lowered to $3 from $4 at Evercore ISI |
| October 8, 2025 10:41 am | — | KeyBanc | $4.00 | $2.85 | TheFly | Health Catalyst price target lowered to $4 from $5 at KeyBanc |
| August 29, 2025 10:38 am | Richard Close | Canaccord Genuity | $5.00 | $3.65 | TheFly | Health Catalyst price target lowered to $5 from $9 at Canaccord |
| August 29, 2025 10:38 am | — | Summit Redstone Partners | $5.00 | $3.65 | TheFly | Health Catalyst price target lowered to $5 from $9 at Canaccord |
Latest News for HCAT
Hsbc Holdings PLC bought a new stake in Health Catalyst, Inc. (NASDAQ: HCAT) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 408,634 shares of the company's stock, valued at approximately $809,000. Hsbc Holdings PLC owned approximately 0.54% of Health Catalyst
SALT LAKE CITY, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that members of senior management will participate in the 2026 Wells Fargo Healthcare Conference, taking place in Boston, on Wednesday, September 9, 2026 and Thursday, September 10, 2026.
Health Catalyst (NASDAQ: HCAT - Get Free Report) and Aclarion (NASDAQ: ACONW - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations. Insider and Institutional Ownership 85.0% of Health Catalyst shares
Health Catalyst, Inc. (NASDAQ: HCAT - Get Free Report) has earned an average rating of "Hold" from the thirteen analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and four have assigned a buy recommendation to the company. The
Health Catalyst (NASDAQ: HCAT - Get Free Report) and Lynx Global Digital Finance (OTCMKTS:CNONF - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership. Earnings and Valuation This table compares
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HCAT.
U.S. House Trading
No House trades found for HCAT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.